Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

2.690 +0.010 (+0.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	614,566
Open	2.750
Bid (Size)	2.670 (100)
Ask (Size)	2.790 (100)
Prev. Close	2.680
Today's Range	2.630 - 2.815
52wk Range	0.7203 - 4.550
Shares Outstanding	36,382,989
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

December 15, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

December 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Performance

YTD	-10.3%	-10.3%
1 Month	-32.6%	-32.6%
3 Month	+43.9%	+43.9%
6 Month	+47.8%	+47.8%
1 Year	+50.3%	+50.3%

More News

Wednesday's session: top gainers and losers ↗

November 26, 2025

Via Chartmill

Which stocks are moving on Wednesday? ↗

November 26, 2025

Via Chartmill

Quince Therapeutics to Participate at Investor Events in December 2025

November 24, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 12, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

November 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

October 09, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

September 25, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

September 11, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 11, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

August 07, 2025

From Quince Therapeutics, Inc.

Via Business Wire

This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

August 05, 2025

Via Benzinga

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

July 16, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

July 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

June 25, 2025

From Quince Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 18, 2025

Via Benzinga

Top movers in Wednesday's after hours session ↗

June 18, 2025

Via Chartmill

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

June 18, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 03, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

May 05, 2025

Via Benzinga

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Quince Therapeutics, Inc. - Common Stock publicly traded?

Yes, Quince Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Quince Therapeutics, Inc. - Common Stock trade on?

Quince Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Quince Therapeutics, Inc. - Common Stock?

The ticker symbol for Quince Therapeutics, Inc. - Common Stock is QNCX on the Nasdaq Stock Market

What is the current price of Quince Therapeutics, Inc. - Common Stock?

The current price of Quince Therapeutics, Inc. - Common Stock is 2.690

When was Quince Therapeutics, Inc. - Common Stock last traded?

The last trade of Quince Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Quince Therapeutics, Inc. - Common Stock?

The market capitalization of Quince Therapeutics, Inc. - Common Stock is 97.87M

How many shares of Quince Therapeutics, Inc. - Common Stock are outstanding?

Quince Therapeutics, Inc. - Common Stock has 98M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.